Details for: KARS1
Associated with
Significant Cells
Cell Significance Index (CSI) scores for the chosen context(s)
-
CSI 18.72rCSI 17.05%PRS 55.56
-
CSI 11.53rCSI 18.34%PRS 34.93
-
CSI 10.67rCSI 34.59%PRS 44.51
-
CSI 10.61rCSI 9.79%PRS 42.13
-
CSI 9.48rCSI 15.14%PRS 44.56
-
CSI 9.32rCSI 9.15%PRS 56.04
-
CSI 8.9rCSI 6%PRS 50.68
-
CSI 8.25rCSI 13.03%PRS 42.05
-
CSI 8.2rCSI 9.9%PRS 48.36
-
CSI 7.64rCSI 10.16%PRS 45.48
-
CSI 7.34rCSI 8.79%PRS 59.94
-
CSI 6.14rCSI 11.93%PRS 42.96
-
CSI 5.16rCSI 29.58%PRS 52.01
-
CSI 5.12rCSI 6.33%PRS 37.24
-
CSI 4.77rCSI 7.37%PRS 39.18
-
CSI 4.67rCSI 7.17%PRS 47.72
-
CSI 4.49rCSI 3.48%PRS 41.37
-
CSI 4.45rCSI 12.76%PRS 57.94
-
CSI 4.37rCSI 7.03%PRS 32.66
-
CSI 4.21rCSI 12.42%PRS 45.17
-
CSI 3.81rCSI 8.69%PRS 40.02
-
CSI 3.7rCSI 6.52%PRS 49.4
-
CSI 3.62rCSI 23.31%PRS 63.94
-
CSI 3.45rCSI 8.76%PRS 37.82
-
CSI 3.4rCSI 5.41%PRS 51.14
-
CSI 3.26rCSI 3.21%PRS 43.3
-
CSI 3.12rCSI 5.49%PRS 39.79
-
CSI 3.1rCSI 2.06%PRS 45.17
-
CSI 3.1rCSI 5.5%PRS 25.91
-
CSI 3.02rCSI 4.34%PRS 33.25
-
CSI 3.02rCSI 4.11%PRS 68.76
-
CSI 3.02rCSI 8.73%PRS 43.73
-
CSI 2.87rCSI 2%PRS 53.46
-
CSI 2.85rCSI 2.74%PRS 41.75
-
CSI 2.8rCSI 2.25%PRS 62.38
-
CSI 2.7rCSI 1.88%PRS 49.11
-
CSI 2.66rCSI 5.08%PRS 57.7
-
CSI 2.6rCSI 2.71%PRS 40.87
-
CSI 2.59rCSI 2.83%PRS 44.86
-
CSI 2.52rCSI 2.38%PRS 42.33
-
CSI 2.48rCSI 2.56%PRS 58.36
-
CSI 2.45rCSI 5.6%PRS 40.52
-
CSI 2.36rCSI 3.51%PRS 44.04
-
CSI 2.36rCSI 1.39%PRS 55.1
-
CSI 2.31rCSI 5.1%PRS 30.5
-
CSI 2.29rCSI 1.64%PRS 53.27
-
CSI 2.29rCSI 2.39%PRS 41.73
-
CSI 2.27rCSI 1.99%PRS 31.22
-
CSI 2.21rCSI 1.74%PRS 47.2
-
CSI 2.21rCSI 3.59%PRS 39.89
-
CSI 2.12rCSI 1.72%PRS 41.59
-
CSI 2.12rCSI 7.67%PRS 60.06
-
CSI 2.11rCSI 1.64%PRS 57.18
-
CSI 2.11rCSI 3.01%PRS 43.93
-
CSI 2.09rCSI 2.41%PRS 35.93
-
CSI 2.08rCSI 4.57%PRS 44.89
-
CSI 2.06rCSI 1.63%PRS 29.87
-
CSI 2.04rCSI 4.91%PRS 58.34
-
CSI 2.02rCSI 1.79%PRS 40.39
-
CSI 2rCSI 1.76%PRS 45.81
-
CSI 1.97rCSI 2.7%PRS 45.71
-
CSI 1.94rCSI 2.65%PRS 35.19
-
CSI 1.93rCSI 2.79%PRS 54.86
-
CSI 1.92rCSI 1.6%PRS 39.69
-
CSI 1.91rCSI 1.52%PRS 62.63
-
CSI 1.91rCSI 2.32%PRS 48.51
-
CSI 1.9rCSI 10.9%PRS 53.19
-
CSI 1.88rCSI 3.77%PRS 31.8
-
CSI 1.83rCSI 3.14%PRS 50.13
-
CSI 1.83rCSI 2.19%PRS 39.34
-
CSI 1.78rCSI 1.87%PRS 43.51
-
CSI 1.75rCSI 8.8%PRS 51.6
-
CSI 1.73rCSI 1.57%PRS 37.9
-
CSI 1.73rCSI 2%PRS 32
-
CSI 1.71rCSI 3.06%PRS 56.87
-
CSI 1.69rCSI 3.2%PRS 50.63
-
CSI 1.66rCSI 1.37%PRS 41.94
-
CSI 1.65rCSI 1.39%PRS 46.2
-
CSI 1.64rCSI 2.27%PRS 40.71
-
CSI 1.63rCSI 1.23%PRS 44.12
-
CSI 1.63rCSI 1.42%PRS 49.72
-
CSI 1.62rCSI 2.92%PRS 35.01
-
CSI 1.59rCSI 3.54%PRS 47.25
-
CSI 1.56rCSI 2.28%PRS 43.93
-
CSI 1.56rCSI 2.92%PRS 61.25
-
CSI 1.55rCSI 1.95%PRS 54.34
-
CSI 1.55rCSI 2.12%PRS 43.79
-
CSI 1.54rCSI 1.65%PRS 39.08
-
CSI 1.53rCSI 2.33%PRS 41.62
-
CSI 1.52rCSI 1.77%PRS 52.07
-
CSI 1.51rCSI 2.08%PRS 61.6
-
CSI 1.51rCSI 2.71%PRS 39.64
-
CSI 1.51rCSI 2.65%PRS 34.12
-
CSI 1.51rCSI 1.13%PRS 59.17
-
CSI 1.5rCSI 1.49%PRS 35.79
-
CSI 1.5rCSI 1.12%PRS 55.31
-
CSI 1.48rCSI 1.2%PRS 42.14
-
CSI 1.47rCSI 2.25%PRS 58.42
-
CSI 1.46rCSI 6.29%PRS 58.05
-
CSI 1.45rCSI 6.28%PRS 57
-
CSI 0.2rCSI 1.0%PRS 72.4%
-
CSI 0.2rCSI 3.7%PRS 64.1%
-
CSI 0.3rCSI 3.4%PRS 75.0%
-
CSI 0.3rCSI 2.6%PRS 67.2%
-
CSI 0.4rCSI 0.8%PRS 38.4%
-
CSI 0.4rCSI 1.8%PRS 52.4%
-
CSI 0.4rCSI 7.5%PRS 88.6%
-
CSI 0.5rCSI 2.6%PRS 52.2%
-
CSI 0.5rCSI 1.8%PRS 56.6%
-
CSI 0.5rCSI 2.5%PRS 64.9%
-
CSI 0.5rCSI 0.7%PRS 50.1%
-
CSI 0.5rCSI 1.8%PRS 54.4%
-
CSI 0.6rCSI 2.5%PRS 63.9%
-
CSI 0.6rCSI 0.7%PRS 38.1%
-
CSI 0.6rCSI 1.6%PRS 55.8%
-
CSI 0.6rCSI 3.4%PRS 56.2%
-
CSI 0.7rCSI 1.4%PRS 61.1%
-
CSI 0.8rCSI 1.7%PRS 56.2%
-
CSI 0.8rCSI 0.7%PRS 48.1%
-
CSI 0.8rCSI 3.6%PRS 39.7%
-
CSI 0.8rCSI 2.9%PRS 57.0%
-
CSI 0.8rCSI 3.3%PRS 63.0%
-
CSI 0.9rCSI 2.2%PRS 54.4%
-
CSI 0.9rCSI 2.8%PRS 49.1%
-
CSI 0.9rCSI 2.7%PRS 59.0%
-
CSI 1.0rCSI 2.7%PRS 55.8%
-
CSI 1.0rCSI 1.6%PRS 57.3%
-
CSI 1.1rCSI 3.6%PRS 51.3%
-
CSI 1.1rCSI 1.1%PRS 46.9%
-
CSI 1.1rCSI 1.6%PRS 49.9%
-
CSI 1.1rCSI 3.1%PRS 59.9%
-
CSI 1.1rCSI 1.6%PRS 48.6%
-
CSI 1.1rCSI 2.1%PRS 64.5%
-
CSI 1.1rCSI 1.8%PRS 46.4%
-
CSI 1.1rCSI 1.7%PRS 38.0%
-
CSI 1.1rCSI 1.3%PRS 56.9%
-
CSI 1.1rCSI 1.7%PRS 42.8%
-
CSI 1.1rCSI 1.4%PRS 50.4%
-
CSI 1.2rCSI 2.1%PRS 68.0%
-
CSI 1.2rCSI 2.9%PRS 39.3%
-
CSI 1.2rCSI 2.5%PRS 63.5%
-
CSI 1.2rCSI 1.8%PRS 51.1%
-
CSI 1.2rCSI 1.5%PRS 43.7%
-
CSI 1.2rCSI 2.4%PRS 70.8%
-
CSI 1.2rCSI 2.8%PRS 27.4%
-
CSI 1.2rCSI 1.3%PRS 38.7%
-
CSI 1.3rCSI 2.0%PRS 35.5%
-
CSI 1.3rCSI 1.9%PRS 41.3%
-
CSI 1.3rCSI 1.9%PRS 58.2%
-
CSI 1.3rCSI 1.7%PRS 39.1%
-
CSI 1.3rCSI 1.2%PRS 64.8%
-
CSI 1.3rCSI 2.9%PRS 55.5%
-
CSI 1.3rCSI 1.0%PRS 39.7%
-
CSI 1.3rCSI 0.9%PRS 42.8%
-
CSI 1.4rCSI 3.2%PRS 53.6%
-
CSI 1.4rCSI 1.6%PRS 63.8%
-
CSI 1.4rCSI 3.3%PRS 46.8%
-
CSI 1.4rCSI 1.2%PRS 44.8%
-
CSI 1.5rCSI 6.3%PRS 57.0%
-
CSI 1.5rCSI 6.3%PRS 58.1%
-
CSI 1.5rCSI 2.3%PRS 58.4%
-
CSI 1.5rCSI 1.2%PRS 42.1%
-
CSI 1.5rCSI 1.1%PRS 55.3%
-
CSI 1.5rCSI 1.5%PRS 35.8%
-
CSI 1.5rCSI 1.1%PRS 59.2%
-
CSI 1.5rCSI 2.7%PRS 34.1%
-
CSI 1.5rCSI 2.7%PRS 39.6%
-
CSI 1.5rCSI 2.1%PRS 61.6%
-
CSI 1.5rCSI 1.8%PRS 52.1%
-
CSI 1.5rCSI 2.3%PRS 41.6%
-
CSI 1.5rCSI 1.7%PRS 39.1%
-
CSI 1.6rCSI 2.1%PRS 43.8%
-
CSI 1.6rCSI 2.0%PRS 54.3%
-
CSI 1.6rCSI 2.9%PRS 61.3%
-
CSI 1.6rCSI 2.3%PRS 43.9%
-
CSI 1.6rCSI 3.5%PRS 47.3%
-
CSI 1.6rCSI 2.9%PRS 35.0%
-
CSI 1.6rCSI 1.4%PRS 49.7%
-
CSI 1.6rCSI 1.2%PRS 44.1%
-
CSI 1.6rCSI 2.3%PRS 40.7%
-
CSI 1.7rCSI 1.4%PRS 46.2%
-
CSI 1.7rCSI 1.4%PRS 41.9%
-
CSI 1.7rCSI 3.2%PRS 50.6%
-
CSI 1.7rCSI 3.1%PRS 56.9%
-
CSI 1.7rCSI 2.0%PRS 32.0%
-
CSI 1.7rCSI 1.6%PRS 37.9%
-
CSI 1.8rCSI 8.8%PRS 51.6%
-
CSI 1.8rCSI 1.9%PRS 43.5%
-
CSI 1.8rCSI 2.2%PRS 39.3%
-
CSI 1.8rCSI 3.1%PRS 50.1%
-
CSI 1.9rCSI 3.8%PRS 31.8%
-
CSI 1.9rCSI 10.9%PRS 53.2%
-
CSI 1.9rCSI 2.3%PRS 48.5%
-
CSI 1.9rCSI 1.5%PRS 62.6%
-
CSI 1.9rCSI 1.6%PRS 39.7%
-
CSI 1.9rCSI 2.8%PRS 54.9%
-
CSI 1.9rCSI 2.7%PRS 35.2%
-
CSI 2.0rCSI 2.7%PRS 45.7%
-
CSI 2.0rCSI 1.8%PRS 45.8%
-
CSI 2.0rCSI 1.8%PRS 40.4%
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration
Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.
Legend:
- Query Gene
-
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
- Node Size: Proportional to Target Cell CSI magnitude
- STRING PPI Edge
- Shared Pathway Edge (ONTOLOGY)
Other Information
This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.
Genular Protein ID: 823821768
Symbol: SYK_HUMAN
Name: Lysine--tRNA ligase
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 9278442
Title: Human lysyl-tRNA synthetase accepts nucleotide 73 variants and rescues Escherichia coli double-defective mutant.
PubMed ID: 9278442
PubMed ID: 10952987
Title: The human lysyl-tRNA synthetase gene encodes both the cytoplasmic and mitochondrial enzymes by means of an unusual alternative splicing of the primary transcript.
PubMed ID: 10952987
PubMed ID: 7584044
Title: Prediction of the coding sequences of unidentified human genes. II. The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by analysis of cDNA clones from human cell line KG-1.
PubMed ID: 7584044
PubMed ID: 15616553
Title: The sequence and analysis of duplication-rich human chromosome 16.
PubMed ID: 15616553
DOI: 10.1038/nature03187
PubMed ID: 15489334
Title: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
PubMed ID: 15489334
DOI: 10.1101/gr.2596504
PubMed ID: 5338216
Title: Enzymatic synthesis of diadenosine tetraphosphate and diadenosine triphosphate with a purified lysyl-tRNA synthetase.
PubMed ID: 5338216
PubMed ID: 9878398
Title: Macromolecular assemblage of aminoacyl-tRNA synthetases: identification of protein-protein interactions and characterization of a core protein.
PubMed ID: 9878398
PubMed ID: 14659874
Title: The telomeric protein Rap1 is conserved in vertebrates and is expressed from a bidirectional promoter positioned between the Rap1 and KARS genes.
PubMed ID: 14659874
PubMed ID: 14975237
Title: The function of lysyl-tRNA synthetase and Ap4A as signaling regulators of MITF activity in FcepsilonRI-activated mast cells.
PubMed ID: 14975237
PubMed ID: 12756246
Title: The interaction between HIV-1 Gag and human lysyl-tRNA synthetase during viral assembly.
PubMed ID: 12756246
PubMed ID: 15220430
Title: Cellular distribution of Lysyl-tRNA synthetase and its interaction with Gag during human immunodeficiency virus type 1 assembly.
PubMed ID: 15220430
PubMed ID: 15851690
Title: Human lysyl-tRNA synthetase is secreted to trigger proinflammatory response.
PubMed ID: 15851690
PubMed ID: 18029264
Title: Lysyl-tRNA synthetase interacts with EF1alpha, aspartyl-tRNA synthetase and p38 in vitro.
PubMed ID: 18029264
PubMed ID: 19413330
Title: Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.
PubMed ID: 19413330
DOI: 10.1021/ac9004309
PubMed ID: 19131329
Title: Dissection of the structural organization of the aminoacyl-tRNA synthetase complex.
PubMed ID: 19131329
PubMed ID: 19289464
Title: Dynamic Organization of Aminoacyl-tRNA Synthetase Complexes in the Cytoplasm of Human Cells.
PubMed ID: 19289464
PubMed ID: 19524539
Title: LysRS serves as a key signaling molecule in the immune response by regulating gene expression.
PubMed ID: 19524539
PubMed ID: 19608861
Title: Lysine acetylation targets protein complexes and co-regulates major cellular functions.
PubMed ID: 19608861
PubMed ID: 21269460
Title: Initial characterization of the human central proteome.
PubMed ID: 21269460
PubMed ID: 22223895
Title: Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.
PubMed ID: 22223895
PubMed ID: 22814378
Title: N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.
PubMed ID: 22814378
PubMed ID: 24312579
Title: Reinvestigation of aminoacyl-tRNA synthetase core complex by affinity purification-mass spectrometry reveals TARSL2 as a potential member of the complex.
PubMed ID: 24312579
PubMed ID: 25944712
Title: N-terminome analysis of the human mitochondrial proteome.
PubMed ID: 25944712
PubMed ID: 18272479
Title: Crystal structure of tetrameric form of human lysyl-tRNA synthetase: Implications for multisynthetase complex formation.
PubMed ID: 18272479
PubMed ID: 23159739
Title: Structural switch of lysyl-tRNA synthetase between translation and transcription.
PubMed ID: 23159739
PubMed ID: 26074468
Title: Structural Basis for Specific Inhibition of tRNA Synthetase by an ATP Competitive Inhibitor.
PubMed ID: 26074468
PubMed ID: 20920668
Title: Compound heterozygosity for loss-of-function lysyl-tRNA synthetase mutations in a patient with peripheral neuropathy.
PubMed ID: 20920668
PubMed ID: 23768514
Title: Mutations in KARS, encoding lysyl-tRNA synthetase, cause autosomal-recessive nonsyndromic hearing impairment DFNB89.
PubMed ID: 23768514
PubMed ID: 25330800
Title: Congenital Visual Impairment and Progressive Microcephaly Due to Lysyl-Transfer Ribonucleic Acid (RNA) Synthetase (KARS) Mutations: The Expanding Phenotype of Aminoacyl-Transfer RNA Synthetase Mutations in Human Disease.
PubMed ID: 25330800
PubMed ID: 27891585
Title: Novel mutations in KARS cause hypertrophic cardiomyopathy and combined mitochondrial respiratory chain defect.
PubMed ID: 27891585
DOI: 10.1111/cge.12931
PubMed ID: 28887846
Title: Mutations in KARS cause early-onset hearing loss and leukoencephalopathy: Potential pathogenic mechanism.
PubMed ID: 28887846
DOI: 10.1002/humu.23335
PubMed ID: 30252186
Title: Inhibition of mitochondrial translation in fibroblasts from a patient expressing the KARS p.(Pro228Leu) variant and presenting with sensorineural deafness, developmental delay, and lactic acidosis.
PubMed ID: 30252186
DOI: 10.1002/humu.23657
PubMed ID: 29615062
Title: KARS-related diseases: progressive leukoencephalopathy with brainstem and spinal cord calcifications as new phenotype and a review of literature.
PubMed ID: 29615062
PubMed ID: 30715177
Title: Biallelic KARS pathogenic variants cause an early-onset progressive leukodystrophy.
PubMed ID: 30715177
DOI: 10.1093/brain/awz001
PubMed ID: 31116475
Title: Mutations in KARS cause a severe neurological and neurosensory disease with optic neuropathy.
PubMed ID: 31116475
DOI: 10.1002/humu.23799
PubMed ID: 30737337
Title: Biallelic variants in LARS2 and KARS cause deafness and (ovario)leukodystrophy.
PubMed ID: 30737337
Sequence Information:
- Length: 597
- Mass: 68048
- Checksum: E7770953332D905D
- Sequence:
MAAVQAAEVK VDGSEPKLSK NELKRRLKAE KKVAEKEAKQ KELSEKQLSQ ATAAATNHTT DNGVGPEEES VDPNQYYKIR SQAIHQLKVN GEDPYPHKFH VDISLTDFIQ KYSHLQPGDH LTDITLKVAG RIHAKRASGG KLIFYDLRGE GVKLQVMANS RNYKSEEEFI HINNKLRRGD IIGVQGNPGK TKKGELSIIP YEITLLSPCL HMLPHLHFGL KDKETRYRQR YLDLILNDFV RQKFIIRSKI ITYIRSFLDE LGFLEIETPM MNIIPGGAVA KPFITYHNEL DMNLYMRIAP ELYHKMLVVG GIDRVYEIGR QFRNEGIDLT HNPEFTTCEF YMAYADYHDL MEITEKMVSG MVKHITGSYK VTYHPDGPEG QAYDVDFTPP FRRINMVEEL EKALGMKLPE TNLFETEETR KILDDICVAK AVECPPPRTT ARLLDKLVGE FLEVTCINPT FICDHPQIMS PLAKWHRSKE GLTERFELFV MKKEICNAYT ELNDPMRQRQ LFEEQAKAKA AGDDEAMFID ENFCTALEYG LPPTAGWGMG IDRVAMFLTD SNNIKEVLLF PAMKPEDKKE NVATTDTLES TTVGTSV